BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32676733)

  • 1. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study.
    Duong VH; Begna KH; Kashanian S; Sweet K; Wang ES; Caddell R; Shafer DA; Singh ZN; Baer MR; Al-Kali A
    Ann Hematol; 2020 Sep; 99(9):2119-2124. PubMed ID: 32676733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.
    Portugal RD; Loureiro MM; Garnica M; Pulcheri W; Nucci M
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):52-7. PubMed ID: 25037887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
    Rasekh EO; Osman R; Ibraheem D; Madney Y; Radwan E; Gameel A; Abdelhafiz A; Kamel A; Elfishawi S
    Ann Hematol; 2021 Mar; 100(3):699-707. PubMed ID: 33230570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].
    Arteaga-Ortiz L; Buitrón-Santiago N; Rosas-López A; Rosas-Arzate G; Armengolt-Jiménez A; Aguayo A; López-Karpovitch X; Crespo-Solís E
    Rev Invest Clin; 2008; 60(6):459-69. PubMed ID: 19378832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Daver N; Boumber Y; Kantarjian H; Ravandi F; Cortes J; Rytting ME; Kawedia JD; Basnett J; Culotta KS; Zeng Z; Lu H; Richie MA; Garris R; Xiao L; Liu W; Baggerly KA; Jabbour E; O'Brien S; Burger J; Bendall LJ; Thomas D; Konopleva M
    Clin Cancer Res; 2015 Jun; 21(12):2704-14. PubMed ID: 25724525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of HyperCVAD regimen and CHOP regimen in treating patients with lymphoblastic lymphoma].
    Hu Y; Zhao X; Wu LL; Cai CP; Zhao WL; Wang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):680-4. PubMed ID: 25286699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
    Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcome of children with biphenotypic acute leukemia.
    Al-Seraihy AS; Owaidah TM; Ayas M; El-Solh H; Al-Mahr M; Al-Ahmari A; Belgaumi AF
    Haematologica; 2009 Dec; 94(12):1682-90. PubMed ID: 19713227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
    Hrusak O; de Haas V; Stancikova J; Vakrmanova B; Janotova I; Mejstrikova E; Capek V; Trka J; Zaliova M; Luks A; Bleckmann K; Möricke A; Irving J; Konatkowska B; Alexander TB; Inaba H; Schmiegelow K; Stokley S; Zemanova Z; Moorman AV; Rossi JG; Felice MS; Dalla-Pozza L; Morales J; Dworzak M; Buldini B; Basso G; Campbell M; Cabrera ME; Marinov N; Elitzur S; Izraeli S; Luria D; Feuerstein T; Kolenova A; Svec P; Kreminska O; Rabin KR; Polychronopoulou S; da Costa E; Marquart HV; Kattamis A; Ratei R; Reinhardt D; Choi JK; Schrappe M; Stary J
    Blood; 2018 Jul; 132(3):264-276. PubMed ID: 29720486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
    Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
    Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-hematological and immunophenotypic profile of acute leukemia of ambiguous lineage: A four year experience from a single tertiary care centre of West India.
    Rai V; Brahmbhatt B; Saha A; Thayakaran IP
    Indian J Pathol Microbiol; 2024; 67(1):121-127. PubMed ID: 38358200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
    Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
    [No Abstract]   [Full Text] [Related]  

  • 18. [Outcomes of adult patients with
    Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population.
    Morris K; Weston H; Mollee P; Marlton P; Gill D; Kennedy G
    Leuk Lymphoma; 2011 Jan; 52(1):85-91. PubMed ID: 21133717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosing and treating mixed phenotype acute leukemia: a multicenter 10-year experience in México.
    Deffis-Court M; Alvarado-Ibarra M; Ruiz-Argüelles GJ; Rosas-López A; Barrera-Lumbreras G; Aguayo-González A; López-Karpovitch X; López-Hernández M; Velázquez-Sánchez de Cima S; Zamora-Ortiz G; Crespo-Solís E
    Ann Hematol; 2014 Apr; 93(4):595-601. PubMed ID: 24146232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.